Biogen has pleased their shareholders in the week after they presented more data on their drug related to late-stage Alzheimer’s. The drug is named Aducanumab. On Thursday, the shares of the firm engaged in biotech ended up closing higher by 3.41% as the analysts had pointed to there being no further negatives with the results…